Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. The recommended single-agent dose is 400 mg orally twice a day ...
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
We assessed the survival benefits of sorafenib therapy for advanced HCC in HAIC refractory patients. Methods The study subjects were 191 patients with advanced HCC who had been treated with HAIC.
Hosted on MSN1mon
Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patientsThe median OS was 12.3 months on the sorafenib alone treatment arm (90% CI 10.6–14.3) versus 15.8 months on the sorafenib with SBRT treatment arm (90% CI 11.4–19.2) (hazard ratio [HR] 0.77, ...
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14 , 95–100 (2009). Article CAS Google Scholar ...
Dana Walker, vice president, Opdivo global programme lead, BMS, said: “HCC is the predominant type of liver cancer globally, including in the EU, and when diagnosed at the advanced or unresectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback